Tirzepatide

Common side effects:

• Nausea and vomiting, particularly during dose escalation.
• Diarrhea or constipation affecting gastrointestinal motility.
• Decreased appetite leading to potential unintended caloric deficits.
• Injection site reactions, including mild redness or itching.
• Fatigue or mild dizziness associated with rapid weight loss.

Rare or serious side effects:

• Pancreatitis (inflammation of the pancreas) requiring immediate medical attention.
• Gallbladder disease, including gallstones or cholecystitis.
• Risk of thyroid C-cell tumors, based on rodent studies (black box warning).
• Severe hypoglycemia when combined with insulin or sulfonylureas.

Dual receptor activation defines the unique molecular mechanism of the Tirzepatide peptide. It functions as an imbalanced and biased dual agonist, binding to both GIP and GLP-1 receptors with a higher affinity for GIP compared to native hormones Willard FS et al., 2020. This synergistic activation enhances glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriate glucagon release. Metabolic regulation extends beyond the pancreas, as Tirzepatide profoundly influences central appetite pathways and gastric motility. By slowing gastric emptying and signaling satiety in the hypothalamus, it drastically reduces energy intake and promotes fat mass reduction Heise T et al., 2023. The combined GIP and GLP-1 activity creates a compounded metabolic effect that drives superior weight loss and glycemic control compared to GLP-1 monotherapies.

Synthetic development of Tirzepatide was spearheaded by Eli Lilly and Company to address the limitations of single-target incretin therapies. Researchers engineered the 39-amino acid peptide sequence to mimic native GIP while incorporating a C20 fatty diacid moiety, which extends its half-life and allows for once-weekly subcutaneous administration. This structural innovation marked a significant milestone in peptide engineering for metabolic diseases. Regulatory milestones for Tirzepatide include its initial FDA approval in 2022 under the brand name Mounjaro for the treatment of type 2 diabetes FDA Label. Following the highly successful SURMOUNT clinical trials demonstrating unprecedented weight loss efficacy, the FDA subsequently approved it in 2023 under the brand name Zepbound specifically for chronic weight management FDA Label. Today, it remains a cornerstone therapy in obesity and diabetes management Sinha R et al., 2023.